(0) = 7	
OCT 0 3 2003	

PTO/SB/08B (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
Frademark Office; U.S. DEPARTMENT OF COMMERCE

Und	ekina Paperwork Re	dubtion Ac	t of 1995, no persons ar	e required to respond to a collection	of information unless it contains a valid OMB control nul Complete if Known	\sum	
Substitut	e for form Land			Applicati n Numb r	to be assigned		
INF	ORMATIO	N DIS	CLOSURE	Filing Date	06/20/2003		
			PPLICANT	First Named Inventor	Dongwen Wang		
				Art Unit	to be determined		
	(Use as many s	heets as r	ecessary)	Examiner Name	To be Determined		
Sheet	1	of	2	Attorney Docket Number	5199-101		

Exami Initials	ner	Cite No.1	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Marit			V.L. PATEL et al., "Analysis of the Process of Encoding Guidelines: A Comparison of GFLIF2 and	
Ī			GLIF3," Methods Inf. Med. 2002; 41: 105-13.	
7			YING TAO et al., "Extended Attributes of Event Monitor Systems for Criteria-Based Notification	
+			Modalities." Proc AMIA Symp. 2002;:762-6.	
1			DONGWEN WANG et al., "GLEE-A Model-Driven Execution System for Computer-Based Implementation of	
			"Clinical Practice Guidelines," Proc AMIA Symp. 2002;:855-9.	
	1		DONGWEN WANG et al., "Representation of Clinical Practice Guidelines for Computer-Based	
	1		Implementations," Medinfo. 2001;10(Pt 1):285-9.	
 		-		

					,			
		/ /	1/1		7		Date	-1010
Examiner		1/1	/./	\mathcal{M}	٠/		Considered	1/2/8/0
Signature	IN	vvv	U 1	N	<u> </u>	t citation is in conformance with MPEP 60		sitation if not in conformance and not
			7.7	A		t election is in conformance with MPEP 60	Draw line intough of	ACRUMINION TO THE TOTAL OF THE

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation is attached.

1 Applicant's unique citation designation is attached.

1 Applicant's unique citation is estimated to take 120 minutes to complete to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete operation is process. In application is attached.

1 Applicant's unique citation is not in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

1 Applicant's unique citation is not in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

1 Applicant's unique citation is attached.

1 Applicant's

PTO/SB/08B (04-03) Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	ite for form		u or 1995, no persons ar	e required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known			
Coocaia				Application Number	to be assigned		
INF	ORMATION	DIS	CLOSURE	Filing Dat	06/20/2003		
STA	ATEMENT E	BY A	PPLICANT	First Named Inventor	Dongwen Wang		
	(Use as many she			Art Unit	to be determined		
	(Ose as many sne	eus as n	ecessary)	Examiner Name	To be Determined		
Sheet	2	of	2	Attorney Docket Number	5199-101		

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of					
nitials* No.1 the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.							
Mid		D. WANG et al., "Representation primitives, process models and patient data					
		in computer-interpretable clinical practice guidlines: a literature review of guideline					
		representation models." Int J Med Inf. 2002 Dec 18;68(1-3):59-70.					
		D. WANG., "Translating national childhood immunization guidelines to a computer-based reminder					
		recall system within an immunization registry." Proc AMIA Symp. 1999:994-8.					
		SUSAN CONOVA, "Useful Clinical Guidelines: New Software May Help Make Guidelines Accessible,"					
		In Vivo, Vol. 2, No. 1, 15 Jan. 2003. http://cpmcnet.columbia.edu/news/in-vivo/Vol2_Iss01_jan15_03/i	·				
		:					

		<u> </u>		//_	1. 1			<u> </u>
Examiner					/ //-/	7	Date	12/2/
Signature	1/0	$\mathcal{V}_{\mathcal{V}}$	\mathcal{M}_{l}	1.	NW		Considered	1218105

EXAMINER: Initial if reference onside to whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.